WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 315245
CAS#: 608137-33-3 (mesylate)
Description: Lisdexamphetamine (L-lysine-D-amphetamine; sold as Vyvanse) is a psychostimulant prodrug of the phenethylamine and amphetamine chemical classes. Its molecular structure consists of dextroamphetamine coupled with the essential amino acid L-lysine. Lisdexamfetamine dimesylate is discontinued (DEA controlled substance).
MedKoo Cat#: 315245
Name: Lisdexamfetamine dimesylate
CAS#: 608137-33-3 (mesylate)
Chemical Formula: C15H25N3O
Molecular Weight: 263.38
Elemental Analysis: C, 68.40; H, 9.57; N, 15.95; O, 6.07
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Related CAS #: 608137-32-2 (free base) 608137-33-3 (mesylate)
Synonym: Vyvanse. N(2S)1phenylpropan2ylLlysinamide dimesylate
IUPAC/Chemical Name: (S)-6-amino-2-(((S)-1-phenylpropan-2-yl)amino)hexanamide, dimesylate
InChi Key: QJLWWRIBAQLZDR-FORAGAHYSA-N
InChi Code: InChI=1S/C15H25N3O.2CH4O3S/c1-12(11-13-7-3-2-4-8-13)18-14(15(17)19)9-5-6-10-16;2*1-5(2,3)4/h2-4,7-8,12,14,18H,5-6,9-11,16H2,1H3,(H2,17,19);2*1H3,(H,2,3,4)/t12-,14-;;/m0../s1
SMILES Code: O=C(N)[C@@H](N[C@@H](C)CC1=CC=CC=C1)CCCCN.OS(=O)(C)=O.OS(=O)(C)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO.
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 263.38 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Turgay A, Ginsberg L, Sarkis E, Jain R, Adeyi B, Gao J, Dirks B, Babcock T, Scheckner B, Richards C, Lasser R, Findling RL. Executive function deficits in children with attention-deficit/hyperactivity disorder and improvement with lisdexamfetamine dimesylate in an open-label study. J Child Adolesc Psychopharmacol. 2010 Dec;20(6):503-11. PubMed PMID: 21186969; PubMed Central PMCID: PMC3005278.
2: Wigal SB, Chae S, Patel A, Steinberg-Epstein R. Advances in the treatment of attention-deficit/hyperactivity disorder: a guide for pediatric neurologists. Semin Pediatr Neurol. 2010 Dec;17(4):230-6. PubMed PMID: 21183129.
3: Katic A, Ginsberg L, Jain R, Adeyi B, Dirks B, Babcock T, Scheckner B, Richards C, Lasser R, Turgay A, Findling RL. Clinically Relevant Changes in Emotional Expression in Children With ADHD Treated With Lisdexamfetamine Dimesylate. J Atten Disord. 2010 Dec 20. [Epub ahead of print] PubMed PMID: 21173426.
4: Wigal SB, Kollins SH, Childress AC, Adeyi B. Efficacy and tolerability of Lisdexamfetamine Dimesylate in children with attention-deficit/hyperactivity disorder: sex and age effects and effect size across the day. Child Adolesc Psychiatry Ment Health. 2010 Dec 14;4(1):32. [Epub ahead of print] PubMed PMID: 21156071.
5: Ermer JC, Adeyi BA, Pucci ML. Pharmacokinetic variability of long-acting stimulants in the treatment of children and adults with attention-deficit hyperactivity disorder. CNS Drugs. 2010 Dec 1;24(12):1009-25. doi: 10.2165/11539410-000000000-00000. PubMed PMID: 21090837.
6: Elbe D, Macbride A, Reddy D. Focus on Lisdexamfetamine: A Review of its use in Child and Adolescent Psychiatry. J Can Acad Child Adolesc Psychiatry. 2010 Nov;19(4):303-14. PubMed PMID: 21037922; PubMed Central PMCID: PMC2962544.
7: Dew RE, Kollins SH. Lisdexamfetamine dimesylate: a new option in stimulant treatment for ADHD. Expert Opin Pharmacother. 2010 Dec;11(17):2907-13. Epub 2010 Oct 28. PubMed PMID: 20979573.
8: Wigal SB, Maltas S, Crinella F, Stehli A, Steinhoff K, Lakes K, Schuck S. Reading Performance as a Function of Treatment With Lisdexamfetamine Dimesylate in Elementary School Children Diagnosed With ADHD. J Atten Disord. 2010 Oct 26. [Epub ahead of print] PubMed PMID: 20978273.
9: Manos MJ, Brams M, Childress AC, Findling RL, Lopez FA, Jensen PS. Changes in Emotions Related to Medication Used to Treat ADHD. Part I: A Literature Review. J Atten Disord. 2010 Sep 28. [Epub ahead of print] PubMed PMID: 20876887.
10: Wigal SB, Jun A, Wong AA, Stehli A, Steinberg-Epstein R, Lerner MA. Does prior exposure to stimulants in children with ADHD impact cardiovascular parameters from lisdexamfetamine dimesylate? Postgrad Med. 2010 Sep;122(5):27-34. PubMed PMID: 20861585.